Understanding the guidelines for Interventions in MR. Ali AlMasood

Size: px
Start display at page:

Download "Understanding the guidelines for Interventions in MR. Ali AlMasood"

Transcription

1 Understanding the guidelines for Interventions in MR Ali AlMasood

2 Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe MR Am Heart J. 2002;144(3):524.r pre It is associated with progressive HF symptomatology and an increased mortality.

3

4 Prognostic importance of MR freedom from death any cause freedom from cardiac death survival without heart failure 404 pts with CHF and optimal medical treatment (76.5% ischemic) Mild: 166 patients (41.2%) Moderate:195 patients (48.1%) Severe: 43 patients (10.7%) Agricola E et al. Eur J Heart Fail 2009;11:581-7

5 Prognostic implications of MR 469 pts with CHF and optimal medical and device treatment Bursi F et al.. Eur J Heart Fail 2010;12:382-8

6 Mitral Regurgitation Abnormal valve function may results from Leaflets Supporting apparatus Left ventricle Two important categories of etiology Acute Chronic valence in elderly

7

8 Etiology of MR Valve related LV related

9 Etiology of primary MR Degenerated Rheumatic

10 Etiology of secondary MR Dilated Ischemic

11 Secondary MR It has worse prognosis complex treatment options optimized medical therapy biventricular pacing valve interventions (surgical vs percutaneous) long-term LV assist devices cardiac transplantation.

12 Mechanism of MR

13 Mechanism of MR

14 Surgical correction of FMR Low operative mortality Possible symptomatic and remodeling benefit There is no evidence that elimination of MR in HF patients conveys a survival benefit Surgery is challenging with inferior outcomes than in primary MR

15 Mitral valve repair for MR in heart failure improves symptoms Bach DS, Bolling SF. Am Heart J 1995; 129:1165

16 Mitral valve annuloplasty improves left ventricular function in heart failure

17 Impact of mitral valve annuloplasty on mortality risk in MR & LV dysfunction there is no clearly demonstrable mortality benefit conferred by MVA for significant MR with severe LV dysfunction. Wu AH et al. J Am Coll Cardiol 2005;45:381-7

18 Surgical correction of FMR Most major guidelines recommend against isolated mitral valve surgery in the setting of chronic severe secondary MR Surgery is only recommended in this setting if aortic valve or coronary artery bypass graft (CABG) surgery functional MR surgery, when performed with CABG, has yielded mixed results

19

20

21 ACC/AHA 2014 Guidelines Recommendations COR LOE MV surgery may be considered in symptomatic patients with chronic severe primary MR and LVEF IIb C 30% (stage D) MV repair may be considered in patients with rheumatic mitral valve disease when surgical treatment is indicated if a durable and successful repair is likely or if the reliability of long-term anticoagulation management is questionable IIb B

22 ACC/AHA 2014 Guidelines Recommendations COR LOE Percutaneous MV repair may be considered for severely symptomatic patients (NYHA class III-IV) with chronic severe primary MR (stage D) who have a reasonable life expectancy, but a prohibitive surgical risk because of severe comorbidities IIb B MVR should not be performed for the treatment of isolated severe primary MR limited to less than one half of the posterior leaflet unless MV repair has been attempted and was unsuccessful III: Harm B

23 ACC/AHA 2014 Guidelines Recommendations COR LOE Percutaneous MV repair may be considered for severely symptomatic patients (NYHA class III-IV) with chronic severe primary MR (stage D) who have a reasonable life expectancy, but a prohibitive surgical risk because of severe comorbidities IIb B MVR should not be performed for the treatment of isolated severe primary MR limited to less than one half of the posterior leaflet unless MV repair has been attempted and was unsuccessful III: Harm B

24 ACC/AHA 2014 Recommendations COR LOE MV surgery may be considered in symptomatic patients with chronic severe primary MR and LVEF IIb C 30% (stage D) MV repair may be considered in patients with rheumatic mitral valve disease when surgical treatment is indicated if a durable and successful repair is likely or if the reliability of long-term anticoagulation management is questionable IIb B

25

26

27 Percutaneous Mitral Valve Repair Mitral Clip System implantations performed worldwide. approved for use in high risk or inoperable pts with severe MR suitable anatomic criteria

28 Percentage of patients with 2+ (MR)at base line and 12 M after percutaneous MitraClip

29 Percentage of pts with [NYHA] functional class at baseline and 12 months after MitraClip

30 Trial/Registry Composition by Functional vs Degenerative Etiology

31 ROLE (1) Don t send pts with FMR for Surgery

32 ESC/ EACTS guidelines & ESC focus update 2015 Percutaneous MitraClip therapy may be considered, after heart team discussion, in highrisk patients with either primary or secondary MR

33 Chronic Primary Mitral Regurgitation: Intervention (cont.) Recommendations COR LOE Percutaneous MV repair may be considered for severely symptomatic patients (NYHA class III- IV) with chronic severe primary MR (stage D) who have a reasonable life expectancy, but a prohibitive surgical risk because of severe IIb B comorbidities MVR should not be performed for the treatment of isolated severe primary MR limited to less than one half of the posterior leaflet unless MV repair has been attempted and was unsuccessful III: Harm B

34 ROLE (2) The Heart Team

35 The Heart Team A multidisciplinary Heart Team (interventional cardiologists, cardiac surgeons, anaesthetists, imaging, and heart failure specialists) Heart team role Evaluate all the options Assess the risk benefit ratio Comorbidities

36 The Heart Valve Team Recommendations COR LOE Patients with severe VHD should be evaluated by a multidisciplinary Heart Valve Team when intervention is considered I C

37 ROLE (3) Establish Heart Valve Centers of Excellence

38 Heart Valve Centers of Excellence Consultation with or referral to a Heart Valve Center of Excellence is reasonable when discussing treatment options for 1) asymptomatic patients with severe VHD, 2) patients who may benefit from valve repair versus valve replacement, or 3) patients with multiple comorbidities for whom valve intervention is considered IIa C

39 ROLE (4) Selection is essential for success in choosing the therapy

40 Key anatomic eligibility criteria for percutaneous edge-to-edge repair

41 Unfavorable anatomical conditions for percutaneous edge-to-edge repair

42 ROLE (5) Utilize the imaging techniques

43 Imaging assessment Severity assessment Anatomic suitability Procedure safety & success

44 MR severity assessment

45

46 Contrast-enhanced ECG-gated Cardiac CT

47 Echo vs. MRI Quantitative echo was compared with cardiac MRI in a prospective series of 103 patients with a majority (82%) of primary MR Agreement between the two methods was moderate for regurgitate volume r ¼ 0.6) (correlation 45 of 58 pts with severe MR according to echo were reclassified as mild or moderate using MRI 26 pts who had MRI after surgery, the correlation between reverse (LV) remodeling and indices of MR severity was much higher for MRI than for echo (r ¼ 0.85, P, vs. r ¼ 0.32, P ¼ 0.10, respectively Uretsky S, et al. Am Coll Cardiol 2015;65:

48

49

50

51

52 ROLE (6) Be aware of potential limitation of available techniques

53 Potential Limitations of mitral clip Recurrent MR Need for reoperation Iatrogenic mitral stenosis

54 ROLE (7) Don t undervalue the role of medical therapy

55 Medical Therapy Medical therapy (ACE inhibitors, b-blockers, and aldosterone antagonists) Diuretics for fluid overload vasodilators for hemodynamic compromise Cardiac resynchronization therapy in appropriate candidate

56 Role (8) Stay tuned for the upcoming therapeutic options

57 Ongoing randomized trials COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) MITRA-FR ( percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation ) RESHAPE II-HF (Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation )

58

59 Take Home Message & future direction

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid Patient records 76 y.o. male Hypertension. Dyslipidemia. OPLD. Smoked in the past. Diabetes

More information

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,

More information

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII I, (Alec Vahanian) DO have a financial interest/arrangement or affiliation

More information

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL DISCLOSURES I WILL BE DISCUSSING OFF-LABEL USAGE OF DEVICES RELATED TO TMVR OBJECTIVES

More information

GDMT for percutaneous mitral valve repair

GDMT for percutaneous mitral valve repair GDMT for percutaneous mitral valve repair Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital The 11th Annual Innovations & Trends in Cardiovascular Care New Brunswick, NJ October 18 th 2014 Ted Feldman

More information

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F. Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F. Attizzani, MD UH Harrington Heart and Vascular Institute Interventional Cardiologist/Structural

More information

Mitral Regurgitation

Mitral Regurgitation Mitral Regurgitation Focus on Percutaneous Repair Steven J. Yakubov, MD FACC FSCAI System Chief, Structural Heart Diseaese, OhioHealth John H. McConnell Chair of Advanced Structural Heart Disease Medical

More information

2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease

2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease 2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease Patrick T. O Gara, MD BWH Heart and Vascular Center Professor of Medicine, Harvard Medical School Disclosures NHLBI CTSN Co-chair

More information

Prognostic Impact of FMR

Prognostic Impact of FMR Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years From Medical Therapy to Surgical Repair to Transcatheter Intervention The Interventionalist s View Samin K Sharma, MD, FACC, FSCAI Director

More information

Introducing the COAPT Trial

Introducing the COAPT Trial physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing

More information

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

Burden of Mitral Regurgitation (MR) in the US Why is This Important? Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence

More information

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

More information

Use of MitraClip Beyond Everest Criteria

Use of MitraClip Beyond Everest Criteria Use of MitraClip Beyond Everest Criteria Takashi Matsumoto, MD Sendai Kousei Hospital Sendai, Japan No Disclosure of Financial Interest Introduction The efficacy and safety of the MitraClip therapy was

More information

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Steven F Bolling Professor of Cardiac Surgery University of Michigan Optimal Treatment of Functional MR Steven F Bolling Professor of Cardiac Surgery University of Michigan Functional MR Functional MR in Ischemia Badhwar, Bolling, chapter in: Advances in Heart Failure,

More information

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,

More information

Valvular Intervention

Valvular Intervention Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone

More information

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT and Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac

More information

Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ

Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ Carpentier MV Classification- Leaflet Mobility Normal Increased Decreased Mobility

More information

Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA

Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas, Nevada December 8 11 th, 2013 Ted Feldman MD, FACC, FESC,

More information

Mitral Valve Disease, When to Intervene

Mitral Valve Disease, When to Intervene Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages

More information

Percutaneous Mitral Valve Repair

Percutaneous Mitral Valve Repair Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip

More information

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS

More information

Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M.

Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M. Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott Chairperson: M. Haude Panellists: A. Al Nooryani, M. Al Otaiby Session objectives To learn about the clinical patient profile for

More information

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD

The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New

More information

Percutaneous Repair for MR:

Percutaneous Repair for MR: Percutaneous Repair for MR: Follow-up and longer term outcomes Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital 16th ANGIOPLASTY SUMMIT TCT Asia Pacific 2011 April 27-29 th Seoul, Korea Ted Feldman

More information

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? Prof. Patrizio LANCELLOTTI, MD, PhD GIGA Cardiovascular Sciences, Heart Valve Clinic, University of Liège, CHU

More information

MitraClip: Why, How, and For Whom?

MitraClip: Why, How, and For Whom? MitraClip: Why, How, and For Whom? Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief, JAMA Cardiology

More information

Valvular Guidelines: The Past, the Present, the Future

Valvular Guidelines: The Past, the Present, the Future Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,

More information

I have financial relationships to disclose Honoraria from: Edwards

I have financial relationships to disclose Honoraria from: Edwards I have financial relationships to disclose Honoraria from: Edwards Mitral Valve Annuloplasty in Ischemic Mitral regurgitation Jean François Avierinos Hôpital Timone Marseille August 28, 2012 Ischemic MR

More information

Corrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio

Corrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio Corrective Surgery in Severe Heart Failure Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio Session Objectives 1.) Identify which patients with severe

More information

Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain

Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain Device Landscape 2010 PERCUTANEOUS TECHNIQUES Percutaneous indirect annuloplasty Percutaneous direct annuloplasty Edge to Edge ( E-Valve ) Non

More information

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Disclosures: GE stock, Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Athena Poppas, MD FACC Past ACC Scientific Sessions Chair, ACC Board

More information

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the

More information

Catheter-based mitral valve repair MitraClip System

Catheter-based mitral valve repair MitraClip System Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular

More information

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock

More information

8/31/2016. Mitraclip in Matthew Johnson, MD

8/31/2016. Mitraclip in Matthew Johnson, MD Mitraclip in 2016 Matthew Johnson, MD 1 Abnormal Valve Function Valve Stenosis Obstruction to valve flow during that phase of the cardiac cycle when the valve is normally open. Hemodynamic hallmark - pressure

More information

Functional Mitral Regurgitation; therapeutic continuum overview. Michele Senni. Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII

Functional Mitral Regurgitation; therapeutic continuum overview. Michele Senni. Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII Functional Mitral Regurgitation; therapeutic continuum overview Michele Senni Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII Functional Mitral Regurgitation FMR is not the result

More information

Establishing an Outreach Referral Network

Establishing an Outreach Referral Network Establishing an Outreach Referral Network Rheumatic Fever 15.000.000 people around the world, Children and young adults, 500.000 deaths /year Thousands desabilities Risk Factor Under development Prevalence

More information

The Key Questions in Mitral Valve Interventions. Where Are We in 2018?

The Key Questions in Mitral Valve Interventions. Where Are We in 2018? The Key Questions in Mitral Valve Interventions Where Are We in 2018? Gilles D. DREYFUS, MD, FRCS, FESC Professor of Cardiothoracic Surgery 30 GIORNATE CARDIOLOGICHE TORINESI - OCT 2018 Are guidelines

More information

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ; CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ; Επιµορφωτικά Σεµινάρια Ειδικευοµένων Καρδιολογίας 7 Απριλίου 2012 M Chrissoheris MD FACC THV Department HYGEIA Hospital Degenerative MR (DMR) Usually refers to an anatomic

More information

The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream

The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org

More information

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan Degenerative MR is not Functional MR 2o - Functional MR : Ventricular Problem!!

More information

Valvular heart disease (VHD) is present in 2.5% of the

Valvular heart disease (VHD) is present in 2.5% of the 2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations Richard Matiasz, MD; Vera H. Rigolin, MD Valvular heart disease (VHD) is present in 2.5% of the

More information

Percutaneous mitral valve repair: current techniques and results

Percutaneous mitral valve repair: current techniques and results Percutaneous mitral valve repair: current techniques and results Ted Feldman, M.D., FSCAI, FACC Angioplasty Summit April 25-27 th th 2007 Seoul, Korea Ted Feldman MD, FACC, FSCAI Disclosure Information

More information

Ischemic Mitral Valve Disease: Repair, Replace or Ignore?

Ischemic Mitral Valve Disease: Repair, Replace or Ignore? Ischemic Mitral Valve Disease: Repair, Replace or Ignore? Fabio B. Jatene Full Professor of Cardiovascular Surgery, Medical School, University of São Paulo, Brazil DISCLOSURE I have no financial relationship

More information

Treatment options in ischaemic mitral regurgitation: surgery, clips, devices?

Treatment options in ischaemic mitral regurgitation: surgery, clips, devices? Treatment options in ischaemic mitral regurgitation: surgery, clips, devices? Francisco Leyva Conflicts of interest: FL has received advisory board fees from Medtronic Inc, Sorin, St Jude Medical and Abbot.

More information

Latest therapies for patients with HF. Dr AIGUL BALTABAEVA PhD, FESC, FRCP RBHT & ASPH

Latest therapies for patients with HF. Dr AIGUL BALTABAEVA PhD, FESC, FRCP RBHT & ASPH Latest therapies for patients with HF Dr AIGUL BALTABAEVA PhD, FESC, FRCP RBHT & ASPH ESC HF Guidelines 2016 ESC HF Guidelines 2016: Pharmacological Treatments Pathways blocked by ACE-I, ARB and NI Effect

More information

Contemporary Management of Mitral Regurgitation Tailoring Treatment to The Patient Subset & Clinical Situation

Contemporary Management of Mitral Regurgitation Tailoring Treatment to The Patient Subset & Clinical Situation Contemporary Management of Mitral Regurgitation Tailoring Treatment to The Patient Subset & Clinical Situation Hatim Al Lawati MD, FRCPC, FACC Consultant Interventional Cardiology Sultan Qaboos University

More information

Repair or Replacement

Repair or Replacement Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division

More information

Percutaneous Mitral Valve Repair

Percutaneous Mitral Valve Repair Indiana Chapter of ACC November 15 th,2008 Percutaneous Mitral Valve Repair James B Hermiller, MD, FACC The Care Group, LLC St Vincent Hospital Indianapolis, IN Mechanisms of Mitral Regurgitation Mitral

More information

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Severe left ventricular dysfunction and valvular heart disease: should we operate? Severe left ventricular dysfunction and valvular heart disease: should we operate? Laurie SOULAT DUFOUR Hôpital Saint Antoine Service de cardiologie Pr A. COHEN JESFC 16 janvier 2016 Disclosure : No conflict

More information

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection

More information

Interventional Updates 2016

Interventional Updates 2016 nterventional Updates 2016 Matthew Johnson, MD Dual Antiplatelet Therapy (DAPT ) What is the newest. Can they ever make up there minds???? What is new in the world of TAVR 1 New risk MitraClip getting

More information

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας Dr Χρήστος ΑΛΕΞΙΟΥ MD, PhD, FRCS(Glasgow), FRCS(CTh), CCST(UK) Consultant Cardiothoracic Surgeon Normal Mitral Valve Function Mitral Regurgitation

More information

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000

More information

Percutaneous Mitral Valve Repair

Percutaneous Mitral Valve Repair Percutaneous Mitral Valve Repair Policy Number: Original Effective Date: MM.06.027 08/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/01/2017 Section: Surgery Place(s)

More information

Worldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates

Worldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates Michael Sumners DO Epidemiology Worldwide rheumatic fever is the most common cause of valve disease In industrialized areas, valvular disease of old age predominates Calcific aortic stenosis Functional

More information

Organic mitral regurgitation

Organic mitral regurgitation The best in heart valve disease Organic mitral regurgitation Ewa Szymczyk Department of Cardiology Medical University of Lodz, Poland I have nothing to declare Organic mitral regurgitation leaflet abnormality

More information

MitraClip World Wide Commercial Experience

MitraClip World Wide Commercial Experience MitraClip World Wide Commercial Experience Valves Repaired. Lives Improved. Carlos G. Hernandez, MBA Sr. Product Manager, Strategic Planning Abbott Vascular October, 2014 MitraClip Transcatheter Mitral

More information

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat

More information

Assessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University

Assessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University Assessment and Preparation of Patients with TAVI Rob Tanzola Associate Professor, Queen s University My patient has aortic stenosis and needs non-cardiac surgery Should (s)he get a TAVI? Rob Tanzola Associate

More information

Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.

Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility

More information

Functional Mitral Regurgitation

Functional Mitral Regurgitation Club 35 - The best in heart valve disease - Functional Mitral Regurgitation Steven Droogmans, MD, PhD UZ Brussel, Jette, Belgium 08-12-2011 Euroecho & other Imaging Modalities 2011 No conflicts of interest

More information

What Is the Role of Mitral Repair in Heart Failure?

What Is the Role of Mitral Repair in Heart Failure? ASK THE EXPERTS What Is the Role of Mitral Repair in Heart Failure? Experts discuss treatment strategies for patients with mitral regurgitation progressing to heart failure. WITH WILLIAM WEIR, MD; STEPHEN

More information

Transcatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health

Transcatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health Transcatheter Mitral Innovations, Part II Michael Mack, M.D. Baylor Scott & White Health Conflict of Interest Disclosure Co-PI of the COAPT Trial of MitraClip sponsored by Abbott Vascular Uncompensated

More information

Next Generation Therapies: Aortic, Mitral and Beyond

Next Generation Therapies: Aortic, Mitral and Beyond Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:

More information

Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz

Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for

More information

Percutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today?

Percutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today? Percutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today? Peter S. Fail, MD, FACC, FACP, FSCAI Director of the Cardiac Catheterization Laboratories and Interventional

More information

Imaging MV. Jeroen J. Bax Leiden University Medical Center The Netherlands Davos, feb 2015

Imaging MV. Jeroen J. Bax Leiden University Medical Center The Netherlands Davos, feb 2015 Imaging MV Jeroen J. Bax Leiden University Medical Center The Netherlands Davos, feb 2015 MV/MR: information needed on.. 1. MV anatomy 2. MR etiology - primary vs secondary 3. MR severity quantification

More information

Ischemic Mitral Regurgitation

Ischemic Mitral Regurgitation Ischemic Mitral Regurgitation 1 / 6 2 / 6 3 / 6 Ischemic Mitral Regurgitation Background Myocardial infarction (MI) can directly cause (IMR), which has been touted as an indicator of poor prognosis in

More information

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular

More information

Transcatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President

Transcatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President Transcatheter Mitral & Tricuspid Therapies Bernard J. Zovighian Corporate Vice President We Will Lead and Transform Treatment for Patients with Mitral and Tricuspid Diseases Mitral and Tricuspid Diseases

More information

Valvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD

Valvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD Valvular Heart Disease Transcatheter Valve Therapies October 2016 Brian Whisenant MD Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement

More information

Advanced Mitral Valve Therapies

Advanced Mitral Valve Therapies Advanced Mitral Valve Therapies Mahesh Ramchandani MD, FRCS Chief, Section of Cardiac Surgery A Largely Untreated Patient Population Mitral Regurgitation 2009 U.S. Prevalence Total MR Patients 1,2 4,100,000

More information

Current status: Percutaneous mitral valve therapy

Current status: Percutaneous mitral valve therapy Current status: Percutaneous mitral valve therapy Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital ESC Stockholm 2010 Disclosures Research Grants Abbott, Edwards Consultant Abbott, Edwards 2 Percutaneous

More information

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,

More information

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital

More information

VALVULAR HEART DISEASE AND PULMONARY CIRCULATION

VALVULAR HEART DISEASE AND PULMONARY CIRCULATION ESC CONGRESS HIGHLIGHTS VALVULAR HEART DISEASE AND PULMONARY CIRCULATION N. Ajmone Marsan (Leiden, NL) MD, PhD, FESC Conflicts of Interest None CONTENTS Pulmonary arterial hypertension Rheumatic heart

More information

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such

More information

What the Cardiologist needs to know from Medical Images

What the Cardiologist needs to know from Medical Images What the Cardiologist needs to know from Medical Images Gerald Maurer Department of Cardiology Medical University of Vienna What kinds of Cardiologists Plumbers Electricians Photographers And then there

More information

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?

More information

Gender Differences in Valvular Heart Disease. Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences

Gender Differences in Valvular Heart Disease. Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences Gender Differences in Valvular Heart Disease Linda D. Gillam, MD FESC Disclosure: Core Lab services Edwards Lifesciences Obstacles Interest in gender differences is a relatively new phenomenon Registries/RCT

More information

Percutaneous Valve Interventions. Percutaneous Valve Interventions

Percutaneous Valve Interventions. Percutaneous Valve Interventions Percutaneous Valve Interventions Stanton J. Rowe President, Percutaneous Valve Interventions Edwards is Best Positioned to Capitalize on Percutaneous Valve Opportunities #1 global valve replacement and

More information

Cardiac Valve/Structural Therapies

Cardiac Valve/Structural Therapies Property of Dr. Chad Rammohan Cardiac Valve/Structural Therapies Chad Rammohan, MD FACC Medical Director, El Camino Hospital Cardiac Catheterization Lab Director, Interventional and Structural Cardiology,

More information

Asymptomatic Valvular Disease:

Asymptomatic Valvular Disease: Asymptomatic Valvular Disease: Can Echocardiography Help You Decide When to Intervene? Neil J. Weissman, MD MedStar Health Research Inst at MedStar Washington Hospital Center & Professor of Medicine Georgetown

More information

The Counter HF Clinical Study for Heart Failure

The Counter HF Clinical Study for Heart Failure The Counter HF Clinical Study for Heart Failure CAUTION: C-Pulse is an investigational device. It is limited by Federal (or United States) Law to investigational use only. 13-111-B Agenda Heart Failure

More information

Guideline-Directed Medical Therapy

Guideline-Directed Medical Therapy Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in

More information

What is the Role of Surgical Repair in 2012

What is the Role of Surgical Repair in 2012 What is the Role of Surgical Repair in 2012 The Long-Term Results of Surgery Raphael Rosenhek Department of Cardiology Medical University of Vienna European Society of Cardiology 2012 Munich, August 27th

More information

What Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed?

What Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed? What Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed? Robert J. Siegel, M.D., FACC Nov. 14-15, 2017, Beverly Hills Director, Cardiac Non-Invasive Laboratory

More information

What echo measurements are key prior to MitraClip?

What echo measurements are key prior to MitraClip? APHP CHU Bichat - Claude Bernard What echo measurements are key prior to MitraClip? Eric Brochet,MD Cardiology Department Hopital Bichat Paris France No disclosure Conflict of interest Case 69 y.o man

More information

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)

More information

Index. B B-type natriuretic peptide (BNP), 76

Index. B B-type natriuretic peptide (BNP), 76 Index A ACCESS-EU registry, 158 159 Acute kidney injury (AKI), 76, 88 Annular enlargement, RV, 177 178 Annuloplasty chordal cutting, 113 complete ring, 99 etiology-specific ring, 100 evolution, 98 flexible

More information

MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male

MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification David S Rubenson MD FACC FASE Founding Director, Cardiac Non-Invasive Laboratory Scripps Clinic Medical Group number 1 Rheumatic Mitral Stenosis

More information

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction Role of Stress Echo in Valvular Heart Disease ECHO HAWAII January 15 19, 2018 Kenya Kusunose, MD, PhD, FASE Tokushima University Hospital Japan Not only ischemia! Cardiomyopathy Prosthetic Valve Diastolic

More information

Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions

Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions Percutaneous Tricuspid Valve Therapies: The Next Frontier? Scott M Lilly, MD PhD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Outline Is the Tricuspid Valve Relevant? Data

More information

Transcatheter mitral valve repair is considered investigational in all situations.

Transcatheter mitral valve repair is considered investigational in all situations. 2.02.30 Transcatheter Mitral Valve Repair Section 2.0 Medicine Subsection 2.02 Cardiology Description Effective Date September 30, 20114 Original Policy Date September 30, 2014 Next Review Date September

More information

Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg

Watchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure

More information

Mitral club: From clinical practice to guidelines: the world upside down

Mitral club: From clinical practice to guidelines: the world upside down Mitral club: From clinical practice to guidelines: the world upside down Christina Chrysohoou Heart Failure Unit 1rst Cardiology Clinic, University of Athens Hippokratio Hospital, Greece Stages of Chronic

More information

SURGICAL TREATMENT OF MODERATE ISCHEMIC MITRAL REGURGITATION: THE CARDIOTHORACIC SURGICAL TRIALS NETWORK

SURGICAL TREATMENT OF MODERATE ISCHEMIC MITRAL REGURGITATION: THE CARDIOTHORACIC SURGICAL TRIALS NETWORK SURGICAL TREATMENT OF MODERATE ISCHEMIC MITRAL REGURGITATION: THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Robert E. Michler, M.D. For the CTSN Investigators AHA Late Breaking Clinical Trials November 18,

More information

Valvular heart disease : Role of medication ( drug and intervention ) Pol.Col.Dr.Kasem Ratanasumawong

Valvular heart disease : Role of medication ( drug and intervention ) Pol.Col.Dr.Kasem Ratanasumawong Valvular heart disease : Role of medication ( drug and intervention ) Pol.Col.Dr.Kasem Ratanasumawong Management of valvular heart disease Accurate diagnosis and disease severity Prevention and treatment

More information